EMD-21374

Single-particle
3.17 Å
EMD-21374 Deposition: 10/02/2020
Map released: 26/02/2020
Last modified: 25/11/2020
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links

EMD-21374

2019-nCoV spike glycoprotein with C3 symmetry imposed

EMD-21374

Single-particle
3.17 Å
EMD-21374 Deposition: 10/02/2020
Map released: 26/02/2020
Last modified: 25/11/2020
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Sample Organism: Severe acute respiratory syndrome coronavirus 2
Sample: SARS-CoV-2 spike glycoprotein

Deposition Authors: Wrapp D, Wang N, McLellan JS
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.
Wrapp D , Wang N , Corbett KS , Goldsmith JA , Hsieh CL , Abiona O , Graham BS , McLellan JS
(2020) Science , 367 , 1260 - 1263
PUBMED: 32075877
DOI: doi:10.1126/science.abb2507
ISSN: 1095-9203
ASTM: SCIEAS
Abstract:
The outbreak of a novel coronavirus (2019-nCoV) represents a pandemic threat that has been declared a public health emergency of international concern. The CoV spike (S) glycoprotein is a key target for vaccines, therapeutic antibodies, and diagnostics. To facilitate medical countermeasure development, we determined a 3.5-angstrom-resolution cryo-electron microscopy structure of the 2019-nCoV S trimer in the prefusion conformation. The predominant state of the trimer has one of the three receptor-binding domains (RBDs) rotated up in a receptor-accessible conformation. We also provide biophysical and structural evidence that the 2019-nCoV S protein binds angiotensin-converting enzyme 2 (ACE2) with higher affinity than does severe acute respiratory syndrome (SARS)-CoV S. Additionally, we tested several published SARS-CoV RBD-specific monoclonal antibodies and found that they do not have appreciable binding to 2019-nCoV S, suggesting that antibody cross-reactivity may be limited between the two RBDs. The structure of 2019-nCoV S should enable the rapid development and evaluation of medical countermeasures to address the ongoing public health crisis.